Vicair (Tablets) Instructions for Use
ATC Code
A02BX (Other drugs for the treatment of gastric and duodenal ulcers and GERD)
Clinical-Pharmacological Group
A drug with antacid, astringent, anti-inflammatory, and antispasmodic action
Pharmacotherapeutic Group
Intestinal antiseptic and astringent
Pharmacological Action
A combined medicinal product that exerts astringent, antacid, laxative, and antispasmodic action.
Bismuth subnitrate forms a protective film on the gastric mucosa, exerting anti-inflammatory, bactericidal, and reparative effects.
Magnesium carbonate reduces the acidity of gastric juice and decreases pepsin activity.
The calamus included in this composition, which has an antispasmodic action, and the buckthorn, which has a laxative action, contribute to the improvement of intestinal transit.
Indications
Use for the treatment of the following gastrointestinal conditions.
- Gastric and duodenal ulcer.
- Hyperacid gastritis accompanied by constipation.
ICD codes
| ICD-10 code | Indication |
| K25 | Gastric ulcer |
| K26 | Duodenal ulcer |
| K27 | Peptic ulcer |
| K29 | Gastritis and duodenitis |
| ICD-11 code | Indication |
| DA42.Z | Gastritis, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA60.Z | Gastric ulcer, unspecified |
| DA61 | Peptic ulcer of unspecified site |
| DA63.Z | Duodenal ulcer, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally as tablets.
Take the tablets after meals with a sufficient amount of water.
The typical adult dosage is one to two tablets taken two to three times daily.
Adjust the exact dosage and duration of treatment based on the specific indication, the patient’s age, and the clinical situation.
The maximum daily dose must not be exceeded.
Do not use for more than two months without consulting a physician.
Do not chew the tablets; swallow them whole.
Maintain an interval of at least two hours between the intake of this product and other oral medications, particularly tetracycline antibiotics.
The dosage regimen is individual and must be determined by a healthcare professional.
Adverse Reactions
Possible adverse reactions include loose stools and allergic reactions.
Discontinue use and consult a physician if any adverse reactions occur.
Drug Interactions
Concomitant use with m-cholinoblockers or histamine H2-receptor blockers may reduce the required dosage of this product.
This product reduces the absorption of tetracycline antibiotics.
Avoid concurrent use with other bismuth-containing medicinal products due to the risk of increased bismuth concentration in the blood.
Contraindications
Do not use under the following conditions.
- Hypersensitivity to any component of the combination.
- Hypoacid gastritis, chronic appendicitis, or enterocolitis.
- Chronic renal failure.
- Pregnancy and the lactation period.
- Age under 18 years.
Overdose
Symptoms of overdose may be related to the bismuth component, potentially leading to encephalopathy with long-term use of high doses.
In case of suspected overdose, discontinue the product immediately and initiate symptomatic and supportive treatment.
Use in Pregnancy and Lactation
Contraindicated during pregnancy and during the lactation (breastfeeding) period.
Use in Renal Impairment
Contraindicated in chronic renal failure.
Pediatric Use
Contraindicated in children and adolescents under 18 years of age.
Special Precautions
It is necessary to consider the possibility of developing encephalopathy associated with the accumulation of bismuth in the CNS with long-term use in high doses.
During treatment, stools become black in color.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Tablets: 10 pcs.
Marketing Authorization Holder
Dalkhimpharm, JSC (Russia)
Dosage Form
 |
Vicair | Tablets: 10 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Bismuth subnitrate | 350 mg |
| Calamus rhizomes | 25 mg |
| Buckthorn bark | 25 mg |
| Magnesium carbonate | 400 mg |
| Sodium bicarbonate | 200 mg |
10 pcs. – non-cell contour packaging.
10 pcs. – contour cell packaging.
Tablets: 10, 20, 30, 50, or 100 pcs.
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Form
|
Vicair | Tablets: 10, 20, 30, 50, or 100 pcs. |
Dosage Form, Packaging, and Composition
| Tablets | 1 tab. |
| Bismuth subnitrate | 350 mg |
| Marsh calamus rhizomes | 25 mg |
| Buckthorn bark | 25 mg |
| Magnesium carbonate | 400 mg |
| Sodium bicarbonate | 200 mg |
10 pcs. – non-cell contour packaging (1) – cardboard packs.
10 pcs. – non-cell contour packaging (2) – cardboard packs.
10 pcs. – non-cell contour packaging (3) – cardboard packs.
10 pcs. – non-cell contour packaging (5) – cardboard packs.
10 pcs. – non-cell contour packaging (10) – cardboard packs.
Tablets: 10, 50, or 100 pcs.
Marketing Authorization Holder
Pharmstandard-Tomskkhimpharm OJSC (Russia)
Manufactured By
Pharmstandard-Lexredstva OJSC (Russia)
Dosage Form
|
Vicair | Tablets: 10, 50, or 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets pink or pinkish-lilac in color with white and dark specks, flat-cylindrical in shape, with a bevel and a score.
| 1 tab. | |
| Bismuth subnitrate | 0.35 g |
| Magnesium hydroxycarbonate | 0.4 g |
| Sodium bicarbonate | 0.2 g |
| Buckthorn bark | 0.025 g |
| Calamus rhizomes | 0.025 g |
Excipients: potato starch – 0.13 g, stearic acid – 0.0048 g, talc – 0.0152 g.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (10) – cardboard packs.
Tablets: 10 pcs.
Marketing Authorization Holder
Avexima JSC (Russia)
Manufactured By
Irbit Chemical Pharmaceutical Plant, JSC (Russia)
Dosage Form
|
Vicair Avexima | Tablets: 10 pcs. |
Dosage Form, Packaging, and Composition
Tablets grayish-brown in color with a pinkish tint, with white and dark specks, flat-cylindrical in shape, with a score and a bevel.
| 1 tab. | |
| Bismuth subnitrate | 350 mg |
| Magnesium carbonate | 400 mg |
| Sodium bicarbonate | 200 mg |
| Acorus calamus rhizome powder | 25 mg |
| Powder of buckthorn bark | 25 mg |
Excipients: potato starch, stearic acid, talc – to obtain a tablet weighing 1150 mg.
10 pcs. – non-cell contour packaging.
10 pcs. – contour cell packaging (1) – cardboard packs.
![Vicair [Tablets] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Vicair [Tablets] 2")